Please go to Enter Survey & provide your feedback on Ellen Licking's talk on What Cancer Pathways Mean for the Biopharma Industry.
Welcome to the Bio2Device Group

The Bio2Device Group (B2DG) is a premier organization for all San Francisco Bay Area professionals in pharmaceutical, biotech, medical device, diagnostics and other life science industry sectors. Weekly programs are designed to keep members up-to-date with industry news, help them explore other industry sectors, and provide networking opportunities with other life science professionals from all industry sectors and corporate functions. The B2DG also hosts a moderated LinkedIn Group to facilitate communication between members.

Read more...

Our Next Event

What Cancer Pathways Mean for the Biopharma Industry
Ellen Licking - Senior Editor and Analyst - Value & Innovation LLC, a subsidiary of Real Endpoints
05/22/2012 - 8:30am
Sunnyvale City Council Chambers, 456 W. Olive, Sunnyvale, CA (across the street from Sunnyvale Public Library)

Topic Description
Only a few years old, results from existing “cancer pathway” pilots underway at national and regional insurers are being unveiled in 2012. If these experiments in using evidence-based medicine to improve outcomes and lower costs prove successful, drug companies will have to adapt their drug development and commercialization strategies to drive market uptake of their...

Read more...

Syndicate content